Searchable abstracts of presentations at key conferences in endocrinology

ea0081p276 | Adrenal and Cardiovascular Endocrinology | ECE2022

Adrenal lesions - the importance of a careful evaluation

Dias Daniela , Figueiredo Ines , Duarte Cristina , Serra FIlipa , Leichsenring Carlos , Tavora Isabel , Paulo Fernandes Joao , Sapinho Ines

Most differential diagnoses of unilateral adrenal lesions include non-functional adenoma, adrenocortical carcinoma or pheochromocytoma. Primary adrenal lymphoma(PAL) is an extremely uncommon type of primary extranodal non-Hodgkin’s lymphoma(<1%). Most cases are bilateral (~75%), being unilateral PAL scarcely reported. The apparent unilateral involvement of this entity at presentation, in the CT scan/MRI may difficult the diagnosis, delaying the start of chemotherapy. ...

ea0077oc2.5 | Endocrine Cancer and Late Effects | SFEBES2021

A novel MiR-346-Directed DNA damage mechanism is regulated by its interaction with long non-coding RNA, NORAD, in prostate cancer

Fletcher Claire , Orafidiya Folake , Deng Lin , Yuan Wei , Lorentzen Marc , Cyran Oliwia , Varela-Carver Anabel , Constantin Theodora , Dobbs Felix , Figueiredo Ines , Gurel Bora , Parkes Eileen , Bogdan Denisa , Pereira Ronnie , Zhao Shuang (George) , Neeb Antje , Issa Fadi , Hester Joanna , Kudo Hiromi , Liu Yang , Philippou Yiannis , Bristow Robert , Knudsen Karen , Bryant Richard , Feng Felix , Reed Simon , Mills Ian , de Bono Johann , Bevan Charlotte

MiR-346 is an Androgen Receptor (AR)-activating miR that associates with DNA damage response (DDR)-linked transcripts in prostate cancer (PC). MiR-346 induces rapid and extensive DNA damage in PC cells through chromatin association, activation of transcription, R-loop formation and DNA replication stress, leading to checkpoint activation and cell cycle arrest. MiR-346 interacts with lncRNA, NORAD, in PC cells, which functions to maintain mitosis, DDR, and chromosomal integrity...

ea0099oc13.1 | Oral Communications 13: Late Breaking | ECE2024

BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer:

Jimenez-Vacas Juan M , Westaby Daniel , Figueiredo Ines , Rekowski Jan , Pettinger Claire , Gurel Bora , Bogdan Denisa , Buroni Lorenzo , Neeb Antje , Padilha Ana , Taylor Joe , Zeng Wanting , Das Souvik , Hobern Emily , Riisnaes Ruth , Crespo Mateus , Miranda Susana , Ferreira Ana , Hanratty Brian , Nava Rodrigues Daniel , Bertan Claudia , Seed George , Fenor de La Maza Maria de Los Dolores , Guo Christina , Carmichael Juliet , Grochot Rafael , Chandran Khobe , Stavridi Anastasia , Varkaris Andreas , Stylianou Nataly , Hollier Brett , Tunariu Nina , Balk Steven , Carreira Suzanne , Yuan Wei , Nelson Peter , Corey Eva , Haffner Michael , de Bono Johann , Sharp Adam

Background: Treatment resistance in prostate cancer can be the result of multiple different tumour cell adaptations generating castration-resistant prostate cancer (CRPC). Despite advancements in treatment, CRPC remains a highly lethal disease. Some CRPCs become AR independent with loss of AR expression and lineage plasticity, urgently requiring novel therapeutic strategies. BCL2 can be upregulated in some CRPCs and may be a therapeutic target for this disease subset.<p cl...